Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morcos, M.
Right arrow Articles by Nawroth, P. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morcos, M.
Right arrow Articles by Nawroth, P. P.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 51:3532-3544, 2002
© 2002 by the American Diabetes Association, Inc.

Activation of Tubular Epithelial Cells in Diabetic Nephropathy

Michael Morcos1, Ahmed A.R. Sayed1, Angelika Bierhaus1, Benito Yard2, Rüdiger Waldherr3, Wolfgang Merz4, Ingrid Kloeting5, Erwin Schleicher6, Stefani Mentz1, Randa F. Abd el Baki1, Hans Tritschler7, Michael Kasper8, Vedat Schwenger1, Andreas Hamann1, Klaus A. Dugi1, Anne-Marie Schmidt9, David Stern9, Reinhard Ziegler1, Hans U. Haering6, Martin Andrassy1, Fokko van der Woude2, and Peter P. Nawroth1

1 Department of Internal Medicine 1 and Department of Nephrology, University of Heidelberg, Heidelberg, Germany
2 Department of Nephrologie, University Hospital of Mannheim, Mannheim, Germany
3 Gemeinschaftspraxis für Pathologie, Heidelberg, Germany
4 Biochemiezentrum, University of Heidelberg, Germany
5 Department of Laboratory Animal Science, Institute of Pathophysiology, Faculty of Medicine, University Greifswald, Greifswald, Germany
6 Department of Medicine, University of Tuebingen, Tuebingen, Germany
7 Asta Medica, Frankfurt, Germany
8 Department of Anatomy, Department of Pathology and Institute of Food Chemistry, Technical University Dresden, Dresden, Germany
9 College of Surgeons, Columbia University, New York, New York

Previous studies have shown that renal function in type 2 diabetes correlates better with tubular changes than with glomerular pathology. Since advanced glycation end products (AGEs; AGE-albumin) and in particular carboxymethyllysine (CML) are known to play a central role in diabetic nephropathy, we studied the activation of nuclear factor {kappa}B (NF-{kappa}B) in tubular epithelial cells in vivo and in vitro by AGE-albumin and CML. Urine samples from healthy control subjects (n = 50) and type 2 diabetic patients (n = 100) were collected and tested for excretion of CML and the presence of proximal tubular epithelial cells (pTECs). CML excretion was significantly higher in diabetic patients than in healthy control subjects (P < 0.0001) and correlated with the degree of albuminuria (r = 0.7, P < 0.0001), while there was no correlation between CML excretion and HbA1c (r = 0.03, P = 0.76). Urine sediments from 20 of 100 patients contained pTECs, evidenced by cytokeratin 18 positivity, while healthy control subjects (n = 50) showed none (P < 0.0001). Activated NF-{kappa}B could be detected in the nuclear region of excreted pTECs in 8 of 20 patients with pTECs in the urine sediment (40%). Five of eight NF-{kappa}Bp65 antigen-positive cells stained positive for interleukin-6 (IL-6) antigen (62%), while only one of the NF-{kappa}B-negative cells showed IL-6 positivity. pTECs in the urine sediment correlated positively with albuminuria (r = 0.57, P < 0.0001) and CML excretion (r = 0.55, P < 0.0001). Immunohistochemistry in diabetic rat kidneys and a human diabetic kidney confirmed strong expression of NF-{kappa}B in tubular cells. To further prove an AGE/CML-induced NF-{kappa}B activation in pTECs, NF-{kappa}B activation was studied in cultured human pTECs by electrophoretic mobility shift assays (EMSAs) and Western blot. Stimulation of NF-{kappa}B binding activity was dose dependent and was one-half maximal at 250 nmol/l AGE-albumin or CML and time dependent at a maximum of activation after 4 days. Functional relevance of the observed NF-{kappa}B activation was demonstrated in pTECs transfected with a NF-{kappa}B-driven luciferase reporter plasmid and was associated with an increased release of IL-6 into the supernatant. The AGE- and CML-dependent activation of NF-{kappa}Bp65 and NF-{kappa}B-dependent IL-6 expression could be inhibited using the soluble form of the receptor for AGEs (RAGE) (soluble RAGE [sRAGE]), RAGE-specific antibody, or the antioxidant thioctic acid. In addition transcriptional activity and IL-6 release from transfected cells could be inhibited by overexpression of the NF-{kappa}B-specific inhibitor {kappa}B{alpha}. The findings that excreted pTECs demonstrate activated NF-{kappa}B and IL-6 antigen and that AGE-albumin and CML lead to a perpetuated activation of NF-{kappa}B in vitro infer that a perpetuated increase in proinflammtory gene products, such as IL-6, plays a role in damaging the renal tubule.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
W. Wang, L. Soltero, P. Zhang, X. R. Huang, H. Y. Lan, and H. J. Adrogue
Renal inflammation is modulated by potassium in chronic kidney disease: possible role of Smad7
Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1123 - F1130.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
F. Waanders, E. van den Berg, R. Nagai, I. van Veen, G. Navis, and H. van Goor
Renoprotective effects of the AGE-inhibitor pyridoxamine in experimental chronic allograft nephropathy in rats
Nephrol. Dial. Transplant., September 28, 2007; (2007) gfm589v1.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
Y. Hamada, S. Miyata, T. Nii-Kono, R. Kitazawa, S. Kitazawa, S. Higo, M. Fukunaga, S. Ueyama, H. Nakamura, J. Yodoi, et al.
Overexpression of thioredoxin1 in transgenic mice suppresses development of diabetic nephropathy
Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1547 - 1557.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. T. Coughlan, V. Thallas-Bonke, J. Pete, D. M. Long, A. Gasser, D. C. K. Tong, M. Arnstein, S. R. Thorpe, M. E. Cooper, and J. M. Forbes
Combination Therapy with the Advanced Glycation End Product Cross-Link Breaker, Alagebrium, and Angiotensin Converting Enzyme Inhibitors in Diabetes: Synergy or Redundancy?
Endocrinology, February 1, 2007; 148(2): 886 - 895.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. Szabo, A. Biser, R. Benko, E. Bottinger, and K. Susztak
Poly(ADP-Ribose) Polymerase Inhibitors Ameliorate Nephropathy of Type 2 Diabetic Leprdb/db Mice
Diabetes, November 1, 2006; 55(11): 3004 - 3012.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
K. G. Raman, P. L. Sappington, R. Yang, R. M. Levy, J. M. Prince, S. Liu, S. K. Watkins, A. M. Schmidt, T. R. Billiar, and M. P. Fink
The role of RAGE in the pathogenesis of intestinal barrier dysfunction after hemorrhagic shock
Am J Physiol Gastrointest Liver Physiol, October 1, 2006; 291(4): G556 - G565.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. Andrassy, J. Igwe, F. Autschbach, C. Volz, A. Remppis, M. F. Neurath, E. Schleicher, P. M. Humpert, T. Wendt, B. Liliensiek, et al.
Posttranslationally Modified Proteins as Mediators of Sustained Intestinal Inflammation
Am. J. Pathol., October 1, 2006; 169(4): 1223 - 1237.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. C.W. Tang, J. C.K. Leung, L. Y.Y. Chan, A. W.L. Tsang, and K. N. Lai
Activation of Tubular Epithelial Cells in Diabetic Nephropathy and the Role of the Peroxisome Proliferator-Activated Receptor-{gamma} Agonist
J. Am. Soc. Nephrol., June 1, 2006; 17(6): 1633 - 1643.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. M. Starkey, S. J. Haidacher, W. S. LeJeune, X. Zhang, B. C. Tieu, S. Choudhary, A. R. Brasier, L. A. Denner, and R. G. Tilton
Diabetes-Induced Activation of Canonical and Noncanonical Nuclear Factor-{kappa}B Pathways in Renal Cortex.
Diabetes, May 1, 2006; 55(5): 1252 - 1259.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
H. Rahmoune, P. W. Thompson, J. M. Ward, C. D. Smith, G. Hong, and J. Brown
Glucose Transporters in Human Renal Proximal Tubular Cells Isolated From the Urine of Patients With Non-Insulin-Dependent Diabetes
Diabetes, December 1, 2005; 54(12): 3427 - 3434.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
T. Nakamura, T. Sugaya, Y. Kawagoe, Y. Ueda, S. Osada, and H. Koide
Effect of Pitavastatin on Urinary Liver-Type Fatty Acid-Binding Protein Levels in Patients With Early Diabetic Nephropathy
Diabetes Care, November 1, 2005; 28(11): 2728 - 2732.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
J. M. Bohlender, S. Franke, G. Stein, and G. Wolf
Advanced glycation end products and the kidney
Am J Physiol Renal Physiol, October 1, 2005; 289(4): F645 - F659.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
K. Kankova, A. Stejskalova, M. Hertlova, and V. Znojil
Haplotype analysis of the RAGE gene: identification of a haplotype marker for diabetic nephropathy in type 2 diabetes mellitus
Nephrol. Dial. Transplant., June 1, 2005; 20(6): 1093 - 1102.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
K. V. Ramana, B. Friedrich, S. Srivastava, A. Bhatnagar, and S. K. Srivastava
Activation of Nulcear Factor-{kappa}B by Hyperglycemia in Vascular Smooth Muscle Cells Is Regulated by Aldose Reductase
Diabetes, November 1, 2004; 53(11): 2910 - 2920.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. H. Li, W. Wang, X. R. Huang, M. Oldfield, A. M. Schmidt, M. E. Cooper, and H. Y. Lan
Advanced Glycation End Products Induce Tubular Epithelial-Myofibroblast Transition through the RAGE-ERK1/2 MAP Kinase Signaling Pathway
Am. J. Pathol., April 1, 2004; 164(4): 1389 - 1397.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Miele, A. Riboulet, M. A. Maitan, F. Oriente, C. Romano, P. Formisano, J. Giudicelli, F. Beguinot, and E. Van Obberghen
Human Glycated Albumin Affects Glucose Metabolism in L6 Skeletal Muscle Cells by Impairing Insulin-induced Insulin Receptor Substrate (IRS) Signaling through a Protein Kinase C{alpha}-mediated Mechanism
J. Biol. Chem., November 28, 2003; 278(48): 47376 - 47387.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2002 by the American Diabetes Association.